BNGO - Bionano shares gains on positive user experiences of research-only Saphyr system
Bionano Genomics gains ([[BNGO]] +25.4%) after announcing the results and experiences of users of its research use only Saphyr system for optical genome mapping ((OGM)).Featured in day two of Bionano’s five-day Cytogenomics Symposium, presentations by scientists and clinicians suggested that the platform is cost effective, provides actionable information faster, in single assay. It was reported that Saphyr is capable in identifying actionable variants in hematological malignancies detected by several cytogenomic methods combined, as well as additional variants missed by traditional methods.According to presentations at Day three, preliminary readout on Saphyr validation study for brain cancer presents path to solid tumor laboratory developed test. It outperforms Oncoscan array for structural variation and copy number variation detection in solid tumors, as well as provides comprehensive and clear picture of structural variation in solid tumors, which has not been possible to date with NGS or array.Presentations at Day four concluded that the Saphyr platform can measure
For further details see:
Bionano shares gains on positive user experiences of research-only Saphyr system